TY - JOUR
T1 - Neuropsychological impairment in amyotrophic lateral sclerosis–frontotemporal spectrum disorder
AU - Abrahams, Sharon
N1 - Acknowledgements: The work based at the University of Edinburgh focusing on the Edinburgh Cognitive and Behavioural ALS Screen and the Dimensional Apathy Scale was funded by the Motor Neurone Disease Association, MND Scotland and the ALS Association. The work described at Edinburgh was undertaken with the help of the MND-Cognition research team Thomas Bak, Judy Newton, Suvankar Pal, Siddharthan Chandran, Ratko Radakovic, Chris Crockford, Elaine Niven, Caroline McHutchison, Debbie Gray, Lewis Pettitt and Elaine Niven. The work is also supported by the Euan Macdonald Centre for MND Research and the Anne Rowling Regenerative Neurology Clinic. In addition to the above I would like to thank my collaborators including Orla Hardiman, Ammar Al Chalabi, Zach Simmons, Michael Benatar, Laura Goldstein and Nigel Leigh. Most importantly I would like to thank all the people with neurodegenerative disease and their families who have helped with this research.
PY - 2023/11
Y1 - 2023/11
N2 - Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with a rapid course, characterized by motor neuron dysfunction, leading to progressive disability and death. This Review, which is aimed at neurologists, psychologists and other health professionals who follow evidence-based practice relating to ALS and frontotemporal dementia (FTD), examines the neuropsychological evidence that has driven the reconceptualization of ALS as a spectrum disorder ranging from a pure motor phenotype to ALS–FTD. It focuses on changes in cognition and behaviour, which vary in severity across the spectrum: around 50% individuals with ALS are within the normal range, 15% meet the criteria for ALS–FTD, and the remaining 35% are in the mid-spectrum range with milder and more focal impairments. The cognitive impairments include deficits in verbal fluency, executive functions, social cognition and language, and apathy is the most prevalent behavioural change. The pattern and severity of cognitive and behavioural change predicts underlying regional cerebral dysfunction from brain imaging and post-mortem pathology. Our increased recognition of cognition and behaviour as part of the ALS phenotype has led to the development and standardization of assessment tools, which have been incorporated into research and clinical care. Measuring change over the course of the disease is vital for clinical trials, and neuropsychology is proving to be a biomarker for the earliest preclinical changes.
AB - Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with a rapid course, characterized by motor neuron dysfunction, leading to progressive disability and death. This Review, which is aimed at neurologists, psychologists and other health professionals who follow evidence-based practice relating to ALS and frontotemporal dementia (FTD), examines the neuropsychological evidence that has driven the reconceptualization of ALS as a spectrum disorder ranging from a pure motor phenotype to ALS–FTD. It focuses on changes in cognition and behaviour, which vary in severity across the spectrum: around 50% individuals with ALS are within the normal range, 15% meet the criteria for ALS–FTD, and the remaining 35% are in the mid-spectrum range with milder and more focal impairments. The cognitive impairments include deficits in verbal fluency, executive functions, social cognition and language, and apathy is the most prevalent behavioural change. The pattern and severity of cognitive and behavioural change predicts underlying regional cerebral dysfunction from brain imaging and post-mortem pathology. Our increased recognition of cognition and behaviour as part of the ALS phenotype has led to the development and standardization of assessment tools, which have been incorporated into research and clinical care. Measuring change over the course of the disease is vital for clinical trials, and neuropsychology is proving to be a biomarker for the earliest preclinical changes.
U2 - 10.1038/s41582-023-00878-z
DO - 10.1038/s41582-023-00878-z
M3 - Review article
SN - 1759-4758
VL - 19
SP - 655
EP - 667
JO - Nature Reviews Neurology
JF - Nature Reviews Neurology
IS - 11
ER -